Delivery Order SPE2DB20D1100-SPE2DB25FB8V5
- Not listed
- The Defense Logistics Agency (DLA) awarded a $30,081.66 delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of RINVOQ ER 45 mg tablets (28-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of April 25, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child delivery order, this award falls under...
- The Defense Logistics Agency awarded a delivery order valued at $26,154.99 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of RINVOQ ER 30 mg tablets (quantity: 30-unit bottles). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $31.8K delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of June 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $17,605.35 on August 20, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 21, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child contract...
- The Defense Logistics Agency awarded a $32,318.92 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, valued at $7,386.40 for the supply of RINVOQ ER 15 mg tablets (30-count units). This is a firm fixed price delivery order with an ultimate completion date of June 2, 2025, and represents a non-competitive set-aside award. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's headquarters. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 mg tablets (30-count units) on November 13, 2025, with a ceiling value of $3,323.05 and an ultimate completion date of November 14, 2025. This non-set-aside competitive award leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a substantial value of $999,999,999.00 and...
- The Defense Logistics Agency awarded a delivery order valued at $6,223.32 to AmerisourceBergen Drug Corp on May 30, 2025, for RINVOQ ER 15 mg tablets (30-count units), with final delivery scheduled for June 2, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract (SPE2DX)...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $3,230.00 by the Defense Logistics Agency on July 30, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This firm fixed-price, non-set-aside contract is scheduled for completion by July 31, 2025, with performance occurring at the vendor's Conshohocken facility. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for RINVOQ ER 30 mg tablets in a quantity of 30 units, with a ceiling value of $9,594.18. This is a firm fixed-price, non-set-aside delivery order that represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FB8V5Delivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $3,171.06 on April 22, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, with performance to be completed by April 23, 2025, and fulfillment based in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The company maintains an extensive portfolio of federal contract awards with the DLA Medical Supply Chain, supplying specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This specific delivery order for RINVOQ ER, a rheumatoid arthritis treatment, exemplifies the company's role in providing specialty pharmaceuticals to support Defense Health Agency operations and other government healthcare systems through flexible contract vehicles.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 4/22/25 |